P3.01-102 Potential Predictors of Unexpected Readmission After Lung Resection S. Uchida, Y. Yoshida, K. Asakura, K. Nakagawa, S. Watanabe Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo/JP Background: Postoperative unexpected readmissions are sentinel events that negatively impact patients. Previous analyses of risk factors of unexpected readmission after lung resection have identified several predictive factors. However, both the operative procedures and perioperative care can vary between institutions. The current study aimed to investigate the incidence levels and potential predictors of unexpected readmission after lung cancer surgery at our institution. Method: Patients who underwent lung resection for primary lung cancers between January 2016 and December 2017 at our institution were enrolled in this study. Operative procedures included pneumonectomy, lobectomy, segmentectomy, and wedge resection. Pleural biopsy and unresectable cases were excluded from this study. Unexpected readmissions were defined as an unscheduled readmission after surgery to our hospital. All patients were examined at our outpatient clinic within 14 days after initial discharge. Thirty-day readmission rates and diagnoses were edaluated. Univariate analysis was performed to identify perioperative factors associated readmission. Result: During the 24-month study period, 1,000 patients underwent lung resection for primary cancer. The median age was 69 years (32e90 years). Fourteen pneumonectomies, 687 lobectomies, 193 segmentectomies, and 106 wedge resections were performed. The median length of postoperative hospital stay was 4 days (2e117 days).
The 30-day mortality rate was 0.3% (3 of 1,000 patients). Forty-three patients (4.3%) experienced an unexpected readmission within 30 days after discharge. The median interval to readmission from the day of discharge was 10 days (1-29 days). The most common diagnoses for readmission were empyema (n¼11; 26%), exacerbation of interstitial pneumonia (n¼7; 16%), pneumothorax (n¼7; 16%), and pneumonia (n¼5; 12%). The median length of readmission hospital stay was 10 days (2e90 days). Among readmitted patients, 9.3% (4 of 43) had died in the hospital due to exacerbation of interstitial pneumonia. In a univariate analysis, significant factors (p<0.05) associated with increased risk of unexpected readmission were man, smoking history, diabetes mellitus, larger tumor size, positive lymph node, either lobectomy or pneumonectomy, longer operative time, either prolonged air leakage (i.e., more than 5 days) or reoperation for air leakage, longer hospital stay after initial surgery. Conclusion: The unexpected readmission rate after lung resection was 4.3% (n¼43), with respiratory complications (n¼30; 70%) being the most common cause. Four patients (9.3%) died in the hospital due to exacerbation of interstitial pneumonia. Several perioperative factors were identified as risk factors for readmission in this study. Background: Brain metastasis in advanced non-small cell lung cancer (NSCLC) patients is often considered as a terminal stage. Crizotinib is a small-molecule tyrosine kinase inhibitor (TKI) for ALK-rearranged NSCLC patients. Herein we conducted a multi-center retrospective study to explore how crizotinib affects the control of brain metastasis and survival outcomes among advanced ALK-rearranged NSCLC patients with brain metastasis in Chinese population. Method: We reviewed medical records of 484 unselected ALK-positive NSCLC patients treated with crizotinib at five cancer centers in China from January 2013 to November 2017. Patients developing brain metastasis either before or during the crizotinib treatment were enrolled. Survival outcomes were analyzed with Kaplan-Meier method and prognostic factors were analyzed with multivariate COX analysis. Result: A total of 174 patients were enrolled into this study, of whom 95 patients had baseline brain metastasis and 79 patients developed brain metastasis during crizotinib treatment. Among patients with baseline brain metastasis, the median intracranial progression-free survival (PFS) was 15.34 months [95% confidence interval (CI): 10.62-20.07] and median overall survival (OS) was 53.38 months (95%CI: 30.58-76.17). The intracranial objective response rate (ORR) was 17.1%, and the intracranial disease control rate (DCR) was 88.6%. Multivariate COX analysis revealed that patients receiving first-line crizotinib [>first-line vs. first-line, hazard ratio (HR): 2.44, 95%CI: 1.05-5.68, p¼0.038], withtout intracranial progression during crizotinib treatment (with vs. without intracranial progression, HR: 18.68, 95%CI: 2.43-143.31, p¼0.005) were associated with better OS, while age, sex, number of brain lesions, and operation/radiation therapy for brain metastasis were not significantly associated with OS. Among patients developing brain
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